EUVIMEDEUVIMED entdecken
Crossref

Dupilumab therapy for chronic rhinosinusitis with nasal polyps (cRSwNP) in pregnancy

Julia Vossen, Andreas Neumann

Laryngo-Rhino-Otologie · 01.05.2024 · 103 (S 02 S 02) · S320

DOI: 10.1055/s-0044-1785084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.05.2024. Verfasst von Julia Vossen und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rescue therapy with monoclonal antibodies for cRSwNP is now an integral part of rhinologic therapy. Due to the current state of research, it is recommended to suspend the therapy in the case of pregnancy. Research question Does therapy with dupilumab have an effect on the course of pregnancy or the health of the child? Material and methods We report on a 32-year-old female patient with cRSwNP (history of 2x pansinus operation), who had applied eight doses of dupilumab 300mg until she became aware of a pregnancy with 16 weeks of gestation. The course of pregnancy, birth and first weeks of life of the child were followed and a literature search was carried out on all known cases of pregnancy under dupilumab therapy.

Results

The patient (gravida II, para I) had a premature birth in the 34+5th week of gestation with premature rupture of membranes, analogous to the first child (not under dupilumab). The child (weight: 80. percentile (pct.); length: 54. pct.; head circumference: 41. pct.) required CPAP respiratory support for four hours and concomitant partial parenteral nutrition for nine days. The further development of the child was regular (14 weeks old in November 2023). The literature search identified seven studies on dupilumab therapy (for atopic dermatitis and bronchial asthma) with reports of pregnancy (N=54). A further 22 case reports were also found.

Conclusion

Our experience and the research data suggest that the use of dupilumab is also safe in pregnancy. Preterm birth occurred in both Para I (without dupilumab) and Para II (with dupilumab). Our observations may support the decision-making when considering the continuation of dupilumab therapy during pregnancy. Publication History Article published online: 19 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Vossen, J., & Neumann, A. (2024). Dupilumab therapy for chronic rhinosinusitis with nasal polyps (cRSwNP) in pregnancy. Laryngo-Rhino-Otologie, 103(S 02 S 02), S320. https://doi.org/10.1055/s-0044-1785084

Vancouver

Vossen J, Neumann A. Dupilumab therapy for chronic rhinosinusitis with nasal polyps (cRSwNP) in pregnancy. Laryngo-Rhino-Otologie. 2024;103(S 02 S 02):S320. doi:10.1055/s-0044-1785084

BibTeX
@article{Vossen2024,
  author = {Vossen, Julia and Neumann, Andreas},
  title = {Dupilumab therapy for chronic rhinosinusitis with nasal polyps (cRSwNP) in pregnancy},
  journal = {Laryngo-Rhino-Otologie},
  year = {2024},
  volume = {103},
  number = {S 02 S 02},
  pages = {S320},
  doi = {10.1055/s-0044-1785084}
}
Kostenlos starten →